Articles

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College of Cardiology (ACC) Scientific Session in New Orleans. The trial compared the...

April 6, 2011 – A pooled analysis of the SPIRIT II, III, IV and COMPARE trials further reinforces the positive clinical performance of an everolimus eluting coronary stent system.

January 10, 2011 – European CE mark approval was announced today for the Abbott, Absorb drug-eluting bioresorbable coronary stent. It is the first bioresorbable stent to gain regulatory approval...

In the world of endovascular devices, the rule is no longer one size fits all. The recent increase in the variety of stents for percutaneous coronary intervention (PCI) offers the physician of a...

In recent years, many medical device companies saw the underserved lower extremity as an opportunity to enter the market for peripheral artery disease (PAD) treatments. For this reason, device...

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...

In recent years, the U.S. cardiac device market has focused on dynamics in the drug-eluting stent (DES) segment – including events ranging from the 2006 BASKET-LATE trial that caused a tremendous...

Standard drug-eluting stent technology seemed to have taken a backseat at this year’s TCT as cardiologists look forward to the next-generation DES using bioresorbable polymer coatings and totally...

September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent...

Bare metal stents (BMS) were introduced in 1994 as an improvement over balloon angioplasty alone, which had a high restenosis rate of between 30-40 percent. The cobalt-chromium or stainless steel...